Clinical Trials Logo
  1. Home
  2. Multinodular Goiter
  3. NCT02194920

Parathyroid Reimplantation in Forearm Subcutaneous Tissue During Thyroidectomy: a Simple Way to Avoid Ipoparathyroidism and Evaluate Graft Function

Thyroid Carcinoma Clinical Trial

Official title:
Arathyroid Reimplantation in Forearm Subcutaneous Tissue During Thyroidectomy: a Simple Way to Avoid Ipoparathyroidism and Evaluate Graft Function

Clinical Trial Summary

The purpose of this study is to evaluate safety and effectiveness of normal parathyroid tissue reimplantation in forearm subcutaneous tissue in case of accidental removal of parathyroid gland during thyroid surgery.

Clinical Trial Description

n/a

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02194920
Study type Observational
Source University of Roma La Sapienza
Contact
Status Completed
Phase N/A
Start date October 2014
Completion date November 2014
View Details
See also
  Status Clinical Trial Phase
Completed NCT02658513 - Evaluation of Lancet Blood Sampling for Radioiodine Dosimetry in Thyroid Cancer
Withdrawn NCT01707056 - The Effect of Coffee on the Absorption of Thyroid Hormone in Patients With Thyroid Carcinoma N/A
Completed NCT00215605 - Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies Phase 1
Completed NCT06439745 - More Than 50% of the Patients With Clinically Unifocal T1b/Small T2 Node Negative Papillary Thyroid Carcinoma Scheduled for Thyroid Lobectomy May Require Completion Thyroidectomy if the Nodal Status is Evaluated
Terminated NCT04327999 - Effect of Artificial Tears on Radioiodine Levels in the Nasolacrimal Duct System Phase 2
Enrolling by invitation NCT06095362 - Thyroid Cancer and Central Lymph Node Metastases Detection Using Bevacizumab-IRDye800CW Phase 1
Not yet recruiting NCT05949424 - OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults Phase 4
Active, not recruiting NCT02145143 - Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study N/A
Terminated NCT01865838 - A Study Into the Effect of Seprafilm in Open Total Thyroidectomy N/A
Recruiting NCT00749697 - Radioiodine Dosimetry Protocol for Thyroid Cancer Metastases N/A
Enrolling by invitation NCT04411290 - Malignancy Predictors, Bethesda and TI-RADS Scores Correlated With Final Histopathology in Thyroid Diseases
Completed NCT01813136 - Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma Phase 2
Recruiting NCT05668962 - Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC Phase 2
Active, not recruiting NCT02185560 - Prospective, Non-interventional, Post-authorization Safety Study That Includes All Patients Diagnosed as Unresectable Differentiated Thyroid Carcinoma and Treated With Sorafenib
Completed NCT04462471 - Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers Phase 1
Completed NCT01433809 - Biomarkers to Distinguish Benign From Malignant Thyroid Neoplasm N/A
Recruiting NCT00929318 - Influence of Thyroid Hormones on the Woundhealing Process N/A
Completed NCT05178186 - Impact of the COVID-19 Pandemic on Surgery for Thyroid Cancer N/A
Completed NCT02773667 - Renal Tracer Elimination in Thyroid Cancer Patients Treated With 131-Iodine
Completed NCT01013597 - Trial of LBH589 in Metastatic Thyroid Cancer Phase 2